Sorafenib or anthracycline-based chemotherapy for progressive desmoid tumors

IF 6.1 2区 医学 Q1 ONCOLOGY
Cancer Pub Date : 2024-11-14 DOI:10.1002/cncr.35647
Philippos Apolinario Costa MD, Arshia Arora MD, Yannelys Fernandez MD, Irvin Yi, Baylee Bakkila MD, Heng Tan MD, Priscila Barreto Coelho MD, Leticia Campoverde MD, Nicole Hardy, Steven Bialick DO, Andrea Espejo Freire MD, Gina Z. D’Amato MD, Yu-Cherng Channing Chang MD, Jacob Peter Mesenger MD, Ty Subhawong MD, Andrew Haims MD, Michael Hurwitz MD, PhD, Kelly Olino MD, Kiran Turaga MD, Hari Deshpande MD, Jonathan Trent MD, PhD
{"title":"Sorafenib or anthracycline-based chemotherapy for progressive desmoid tumors","authors":"Philippos Apolinario Costa MD,&nbsp;Arshia Arora MD,&nbsp;Yannelys Fernandez MD,&nbsp;Irvin Yi,&nbsp;Baylee Bakkila MD,&nbsp;Heng Tan MD,&nbsp;Priscila Barreto Coelho MD,&nbsp;Leticia Campoverde MD,&nbsp;Nicole Hardy,&nbsp;Steven Bialick DO,&nbsp;Andrea Espejo Freire MD,&nbsp;Gina Z. D’Amato MD,&nbsp;Yu-Cherng Channing Chang MD,&nbsp;Jacob Peter Mesenger MD,&nbsp;Ty Subhawong MD,&nbsp;Andrew Haims MD,&nbsp;Michael Hurwitz MD, PhD,&nbsp;Kelly Olino MD,&nbsp;Kiran Turaga MD,&nbsp;Hari Deshpande MD,&nbsp;Jonathan Trent MD, PhD","doi":"10.1002/cncr.35647","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Desmoid tumors can cause morbidity due to local invasion, potentially being fatal when fast growth compromises vital structures. In this context, a timely treatment response is required. This study aims to compare the activity of sorafenib and anthracycline-containing regimens during the first year of treatment.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>The authors conducted a multi-institutional retrospective analysis of desmoid tumor patients treated with either sorafenib or an anthracycline-containing regimen over 1 year. The primary end point was the overall response rate (ORR). The secondary end points were time to response (TTR), progression-free survival (PFS), and adverse events.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>From 2005 to 2022, 80 patients received sorafenib and 51 received an anthracycline-containing regimen with similar baseline characteristics. The 1-year ORR was 37% for anthracycline and 13% for sorafenib (<i>p</i> = .016). Median best response was –9% (range, –73 to 51) for anthracycline and –4% (range, –69 to 126) for sorafenib. Median TTR was 5.6 months (95% confidence interval [CI], 3.4–7.8) for anthracycline and 8.7 months (95% CI, 6.3–11.1) for sorafenib (<i>p</i> = .2). One-year PFS was 73% (95% CI, 60–86) for anthracycline and 59% (95% CI, 47–71) for sorafenib (<i>p</i> = .3). Common grade 1–2 adverse events for sorafenib were hand-foot syndrome (40%), diarrhea (25%), and fatigue (22%); for anthracycline, they were nausea (31%), fatigue (16%), and rash (14%). Grade 3 events were higher in the anthracycline group, 27% versus 14% (<i>p</i> &lt; .05).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Anthracycline-based therapy provided a greater 1-year response rate than sorafenib but was associated with a higher rate of serious adverse events. Higher-risk desmoid tumors, which need a more timely response, might benefit from anthracycline-based therapies, whereas average-risk tumors could benefit from sorafenib.</p>\n </section>\n </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 1","pages":""},"PeriodicalIF":6.1000,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cncr.35647","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Desmoid tumors can cause morbidity due to local invasion, potentially being fatal when fast growth compromises vital structures. In this context, a timely treatment response is required. This study aims to compare the activity of sorafenib and anthracycline-containing regimens during the first year of treatment.

Methods

The authors conducted a multi-institutional retrospective analysis of desmoid tumor patients treated with either sorafenib or an anthracycline-containing regimen over 1 year. The primary end point was the overall response rate (ORR). The secondary end points were time to response (TTR), progression-free survival (PFS), and adverse events.

Results

From 2005 to 2022, 80 patients received sorafenib and 51 received an anthracycline-containing regimen with similar baseline characteristics. The 1-year ORR was 37% for anthracycline and 13% for sorafenib (p = .016). Median best response was –9% (range, –73 to 51) for anthracycline and –4% (range, –69 to 126) for sorafenib. Median TTR was 5.6 months (95% confidence interval [CI], 3.4–7.8) for anthracycline and 8.7 months (95% CI, 6.3–11.1) for sorafenib (p = .2). One-year PFS was 73% (95% CI, 60–86) for anthracycline and 59% (95% CI, 47–71) for sorafenib (p = .3). Common grade 1–2 adverse events for sorafenib were hand-foot syndrome (40%), diarrhea (25%), and fatigue (22%); for anthracycline, they were nausea (31%), fatigue (16%), and rash (14%). Grade 3 events were higher in the anthracycline group, 27% versus 14% (p < .05).

Conclusion

Anthracycline-based therapy provided a greater 1-year response rate than sorafenib but was associated with a higher rate of serious adverse events. Higher-risk desmoid tumors, which need a more timely response, might benefit from anthracycline-based therapies, whereas average-risk tumors could benefit from sorafenib.

索拉非尼或以蒽环类为基础的化疗治疗进展期类脂膜瘤。
背景:蝶形肿瘤可因局部浸润而导致发病,当快速生长危及重要结构时,则可能致命。在这种情况下,需要及时采取治疗对策。本研究旨在比较索拉非尼和含蒽环类药物方案在治疗第一年的活性:作者对接受索拉非尼或含蒽环类药物治疗一年以上的类脂膜瘤患者进行了一项多机构回顾性分析。主要终点是总反应率(ORR)。次要终点是反应时间(TTR)、无进展生存期(PFS)和不良事件:从2005年到2022年,80名患者接受了索拉非尼治疗,51名患者接受了含蒽环类药物治疗,基线特征相似。蒽环类药物的1年ORR为37%,索拉非尼为13%(p = .016)。蒽环类药物的中位最佳反应为-9%(范围为-73至51),索拉非尼为-4%(范围为-69至126)。蒽环类药物的中位TTR为5.6个月(95% 置信区间[CI],3.4-7.8),索拉非尼为8.7个月(95% CI,6.3-11.1)(P = .2)。蒽环类药物的一年生存率为73%(95% CI,60-86),索拉非尼为59%(95% CI,47-71)(p = .3)。索拉非尼常见的 1-2 级不良事件为手足综合征(40%)、腹泻(25%)和疲劳(22%);蒽环类药物常见的 1-2 级不良事件为恶心(31%)、疲劳(16%)和皮疹(14%)。蒽环类药物组的 3 级事件发生率较高,为 27% 对 14%(P 结论:蒽环类药物组的 3 级事件发生率高于蒽环类药物组:与索拉非尼相比,蒽环类药物治疗的 1 年应答率更高,但与较高的严重不良事件发生率相关。风险较高的类脂膜瘤需要更及时的反应,可能会从蒽环类疗法中获益,而风险一般的肿瘤则可能从索拉非尼疗法中获益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer
Cancer 医学-肿瘤学
CiteScore
13.10
自引率
3.20%
发文量
480
审稿时长
2-3 weeks
期刊介绍: The CANCER site is a full-text, electronic implementation of CANCER, an Interdisciplinary International Journal of the American Cancer Society, and CANCER CYTOPATHOLOGY, a Journal of the American Cancer Society. CANCER publishes interdisciplinary oncologic information according to, but not limited to, the following disease sites and disciplines: blood/bone marrow; breast disease; endocrine disorders; epidemiology; gastrointestinal tract; genitourinary disease; gynecologic oncology; head and neck disease; hepatobiliary tract; integrated medicine; lung disease; medical oncology; neuro-oncology; pathology radiation oncology; translational research
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信